Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

expansion as the leading GPCR immuno-oncology company Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer Rhythm Pharmaceuticals and LG Chem Life Sciences

Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290 Crinetics Pharmaceuticals Cushing’s Syndrome (ADCS) Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals

Tagging GPCRs expressed in cellular compartments such as the nucleus or endosomes presents several pharmaceutical Overall, the pharmaceutical challenges associated with tagging GPCRs expressed in cellular compartments Pharmaceuticals (Basel, Switzerland), 14(5), 439. https://doi.org/10.3390/ph14050439 Chen, K.

inactive conformation using molecular dynamic simulations "The δ-opioid receptor (DOR) is a critical pharmaceutical

given the Society’s conference will be held in Perth next year, in collaboration with the Australasian Pharmaceutical

Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical

Apprentice Head of Human Resource Business Partners Senior Scientist, In vitro pharmacology - Crinetics Pharmaceuticals Senior Director, In vitro pharmacology - Crinetics Pharmaceuticals Explore Dr.

In recent years, pharmaceutical companies have begun to utilize cryo-EM for structure-based drug design

Advances in GPCRs: Structure, Mechanisms, Disease, and Pharmacology Industry News Monash University pharmaceutical Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology Crinetics Pharmaceuticals

Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults Crinetics Pharmaceuticals Update Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 Crinetics Pharmaceuticals

Expertise in Oncology Octant Bio will be at the Goldman Sachs Global Healthcare Conference Crinetics Pharmaceuticals

not only deepens our understanding of a key biological process but also provides a valuable map for pharmaceutical

Poon to Board of Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing

Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases Crinetics Pharmaceuticals

By identifying key β2AR residues that influence efficacy and potency, pharmaceutical researchers can

in nearly all physiological systems make GPCR the largest protein family targeted for development of pharmaceuticals

all symptoms of schizophrenia Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues

amended deal with Gilead on anti-CCR8 antibody InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical

Structural analysis of the human C5a-C5aR1 complex using cryo-electron microscopy Industry News Crinetics Pharmaceuticals

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating

📰 GPCR Weekly News, July 22 to 28, 2024 In the fast-paced world of pharmaceuticals and drug discovery

Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics Crinetics Pharmaceuticals

discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology at Crinetics Pharmaceuticals

immunotherapy drug Trevena Reports Second Quarter 2023 Results and Provides Business Update Crinetics Pharmaceuticals

Reports Financing Highlights Neurocrine Biosciences Provides Development Pipeline Update Crinetics Pharmaceuticals

£3.5M ($4.6M) to Advance Generative AI Antibody Design Platform GPCR Safety Panels Launched Crinetics Pharmaceuticals